Sun Huiting, Xiao Min, Liu Sufen, Shi Ruxia
Department of Gynaecology, The Affiliated Changzhou No. 2 People's Hospital of Nanjing Medical University Changzhou Cancer Hospital, Soochow University, Changzhou, China.
Medicine (Baltimore). 2018 Jul;97(27):e11036. doi: 10.1097/MD.0000000000011036.
Ovarian cancer is the most deadly gynecologic cancer, and the therapy is very difficult. Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2. At present, there are few studies or case reports on apatinib treatment for patients with ovarian cancer.
A 75-year-old Chinese woman had a medical history of ovarian high-grade serous papillary adenocarcinoma, who got many lines of chemotherapy and apatinib-an antiangiogenesis drug therapy. Either alone or in combination, apatinib may extend the survival time of patients with advanced ovarian cancer.
Apatinib may be an option for advanced ovarian cancer after failure of chemotherapy or other targeted therapy. The role of apatinib in the treatment of advanced ovarian cancer needs further study.
卵巢癌是最致命的妇科癌症，治疗非常困难。阿帕替尼是一种新型的靶向血管内皮生长因子受体-2的酪氨酸激酶抑制剂。目前，关于阿帕替尼治疗卵巢癌患者的研究或病例报告较少。
一名75岁的中国女性有卵巢高级别浆液性乳头状腺癌病史，接受了多线化疗及阿帕替尼——一种抗血管生成药物治疗。单独或联合使用阿帕替尼可能会延长晚期卵巢癌患者的生存时间。
阿帕替尼可能是化疗或其他靶向治疗失败后晚期卵巢癌的一种选择。阿帕替尼在晚期卵巢癌治疗中的作用需要进一步研究。
